Market Capitalization (Millions $) |
344 |
Shares
Outstanding (Millions) |
190 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-364 |
Cash Flow (TTM) (Millions $) |
-31 |
Capital Exp. (TTM) (Millions $) |
7 |
I Mab
I mab, also known as immunomodulatory antibody, is a type of monoclonal antibody that is used in immunotherapy for the treatment of certain diseases. It acts by targeting specific proteins on cells of the immune system, thereby modulating immune responses. This can be done by either enhancing or suppressing the activity of immune cells, depending on the specific disease being treated. I mab has shown promising results in treating various conditions such as cancer, autoimmune disorders, and inflammatory diseases. It is typically administered intravenously and may be used in combination with other therapies to improve treatment outcomes.
Company Address: 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai 200124
Company Phone Number: 6057-8000 Stock Exchange / Ticker: NASDAQ IMAB
IMAB is expected to report next financial results on April 30, 2024. |
|
|